Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Selvita S.A.

https://selvita.com/

Latest From Selvita S.A.

Poland’s Ryvu To Feed Galapagos’ R&D Effort

Ryvu Therapeutics has added to its drug discovery collaborators with an early-stage deal with Belgium’s Galapagos. 

 

 

Deals Inflammation

Finance Watch: BioNTech, Vir Launch IPOs But Take US Offerings To Market At A Discount

BioNTech's $150m offering, after a prior large venture capital financing, gives it the third-largest market cap for a newly public drug developer in the US. Also, Innovent raises $300m in Hong Kong offering, Heron leads US follow-ons and Five Prime restructures to save $20m annually.

Financing StartUps and SMEs

Inflection's Lead Series Boosts AUM's Oncology Pipeline

Asian oncology venture gains worldwide rights to novel molecule series from Inflection, giving a leg up to its global ambitions.

Deals Cancer

Venture Funding Deals: I-Mab Is The Mega-Round Leader With $220m Series C

Freeline Therapeutics, I-Mab Biopharma, Kaleido Biosciences and Precision BioSciences raised more than $100m each, but Chinese start-ups continue to bring in some of this year's largest venture capital mega rounds, with $220m in Series C cash to fund development of immuno-oncology and inflammatory disease drug candidates.

Financing StartUps and SMEs
See All

Company Information

  • Industry
  • Contract Research Organization-CRO
  • Pharmaceuticals
  • Services
  • Biotechnology
    • Drug Discovery Tools
      • ADMET
  • Other Names / Subsidiaries
    • Fidelta d.o.o.
UsernamePublicRestriction

Register